European Crohn´s and Colitis Organisation - ECCO - OP21 Positivity thresholds of total infliximab and adalimumab anti-drug antibody assay: The prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug
Children | Free Full-Text | Therapy Strategies for Children Suffering from Inflammatory Bowel Disease (IBD)—A Narrative Review | HTML
European Crohn´s and Colitis Organisation - ECCO - P533 Adalimumab 80mg every other week in inflammatory bowel disease: Treatment intensification outcomes in real life clinical practice
Evidence-based clinical practice guidelines for inflammatory bowel disease 2020 | SpringerLink
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra
Rational Combination Therapy to Overcome the Plateau of Drug Efficacy in Inflammatory Bowel Disease - Gastroenterology
Evidence-based clinical practice guidelines for inflammatory bowel disease 2020 | SpringerLink
European Crohn´s and Colitis Organisation - ECCO - P533 Adalimumab 80mg every other week in inflammatory bowel disease: Treatment intensification outcomes in real life clinical practice
First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? | Nature Reviews Gastroenterology & Hepatology
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical M
PDF) DOP064 ECCO expert consensus and topical review on treatment exit strategies in inflammatory bowel disease
ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease
European Crohn´s and Colitis Organisation - ECCO - DOP62 Immunogenicity to second anti-TNF therapy (IMSAT): Implications for sequencing of biologic therapy
PDF) Biologics recommendations in the ECCO guidelines on therapeutics in Crohn's disease: Medical treatment
Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY) - Gastroenterology
Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia
Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring - Gastroenterology
Neel Heerasing (@gastrodr_nh) / Twitter
Drugs and anti-drug antibody levels in the management of patients with inflammatory bowel disease | Gastroenterología y Hepatología (English Edition)
Evidence-based clinical practice guidelines for inflammatory bowel disease 2020 | SpringerLink
Proactive therapeutic drug monitoring of adalimumab for pediatric Crohn's disease patients: A cost‐effectiveness analysis - Yao - 2021 - Journal of Gastroenterology and Hepatology - Wiley Online Library
Immunomodulator Withdrawal From Anti-TNF Therapy Is Not Associated With Loss of Response in Inflammatory Bowel Disease - Clinical Gastroenterology and Hepatology
Managing complex perianal disease after anti-TNF failure: Where to go next? - ScienceDirect
Frontiers | Multi-utility of therapeutic drug monitoring in inflammatory bowel diseases
![PDF] [Comparison of Treatment Guidelines for Ulcerative Colitis: Role of Biologics]. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/0a8e924d287b22861a1cb440f147aa0618dbc982/2-Table1-1.png "PDF] [Comparison of Treatment Guidelines for Ulcerative Colitis: Role of Biologics]. | Semantic Scholar")
PDF] [Comparison of Treatment Guidelines for Ulcerative Colitis: Role of Biologics]. | Semantic Scholar
European Crohn´s and Colitis Organisation - ECCO - DOP62 Immunogenicity to second anti-TNF therapy (IMSAT): Implications for sequencing of biologic therapy
